5821374
Last Update Posted: 2024-06-04
Recruiting has not begun
All Genders accepted | 18 Years-70 Years |
10 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Deucravacitinib in PG
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
Eligibility
Relevant conditions:
Pyoderma Gangrenosum
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Data sourced from ClinicalTrials.gov